首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >The Antihypertensive Efficacy of Chlorthalidone and Telmisartan in Indian Hypertensive Patients who were Uncontrolled with Hydrochlorothiazide and Telmisartan Combination-A Prospective and an Open Label Study
【2h】

The Antihypertensive Efficacy of Chlorthalidone and Telmisartan in Indian Hypertensive Patients who were Uncontrolled with Hydrochlorothiazide and Telmisartan Combination-A Prospective and an Open Label Study

机译:氯噻酮和替米沙坦在未接受氢氯噻嗪和替米沙坦联合治疗的印度高血压患者中的降压功效-前瞻性和开放标签研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: The primary objective of this study was to evaluate the antihypertensive efficacy of the chlorthalidone and telmisartan combination in Indian hypertensive patients who remained uncontrolled after taking the hydrochlorothiazide and telmisartan combination.>Methods: A total of 100 eligible patients were enrolled in this prospective, open label study. The patients were given telmisartan (40 mg) and chlorthalidone (12.5 mg), who had not achieved the target blood pressure (140/90 mmHg) despite taking the combination of telmisartan (40 mg) and hydrochlorothiazide (12.5 mg). The assessment was done at the end of 4 weeks and 8 weeks.>Results: The mean SBP and DBP after taking telmisartan (40 mg) and hydrochlorothiazide (12.5 mg) were 154.88±9.57 (range 144 to 160) mmHg and 99.37±2.78 (range 92 to 106). At the end of 4 weeks of being on telmisartan (40 mg) and chlorthalidone (12.5 mg), the mean SBP and DBP were 145.56±5.12 (range 134 to 158) mmHg and 95.14±4.27 (range 84 to 100) mmHg. Significant falls in the SBP (5.32±2.64) and DBP (4.18±2.48) were noted at the end of the 4 week therapy. They were sustained at the end of 8 weeks also. The SBP target (<140 mmHg) was achieved in 24 % patients. The DBP target (<90 mmHg) was achieved in 19% patients. The combined SBP and DBP target (<140/90 mmHg) was achieved in 15% patients. No significant clinical adverse events were reported. Similar falls in the SBP and DBP were noted in the subgroups (smokers, females, diabetics, etc).>Conclusions: The hypertensive patients who do not achieve the target blood pressures on telmisartan and hydrochlorothiazide can be switched on to the telmisartan and chlorthalidone combination. This combination is effective and well tolerated.
机译:>目的:该研究的主要目的是评估氯噻酮和替米沙坦联合治疗对接受高血压治疗的印度高血压患者的降压疗效。印度高血压患者服用氢氯噻嗪和替米沙坦联合治疗后仍无法控制。>方法:共有100名合格患者参加了这项前瞻性开放标签研究。患者服用替米沙坦(40 mg)和氯噻酮(12.5 mg),尽管服用替米沙坦(40 mg)和氢氯噻嗪(12.5 mg)仍未达到目标血压(140/90 mmHg)。在第4周和第8周结束时进行评估。>结果:服用替米沙坦(40 mg)和氢氯噻嗪(12.5 mg)后的平均SBP和DBP为154.88±9.57(范围144至160)毫米汞柱和99.37±2.78(范围从92到106)。服用替米沙坦(40 mg)和氯噻酮(12.5 mg)4周后,平均SBP和DBP为145.56±5.12(范围134至158)mmHg和95.14±4.27(范围84至100)mmHg。在4周治疗结束时,注意到SBP(5.32±2.64)和DBP(4.18±2.48)显着下降。他们也维持了8个星期。在24%的患者中达到了SBP目标(<140 mmHg)。 19%的患者达到了DBP目标(<90 mmHg)。 15%的患者实现了SBP和DBP的联合目标(<140/90 mmHg)。没有重大临床不良事件的报道。在亚组(吸烟者,女性,糖尿病患者等)中,SBP和DBP也有类似的下降。>结论:不能达到替米沙坦和氢氯噻嗪达到目标血压的高血压患者。替米沙坦和氯噻酮合用。这种组合是有效的且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号